ArticleCancer science2010

Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.

Sung Yong Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.